McNeil Products Ltd

Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UG
Medical Information Direct Line: 01344 864042
Medical Information e-mail: medinfo@its.jnj.com


Summary of Product Characteristics last updated on the eMC: 10/03/2008
SPC Anusol HC Suppositories


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Anusol HC Suppositories


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each suppository contains:

Hydrocortisone acetate 10mg

Bismuth subgallate 59mg

Bismuth oxide 24mg

Balsam Peru 49mg

Benzyl benzoate 33mg

Zinc oxide 296mg


Go to top of the page
3. PHARMACEUTICAL FORM

White/off white suppository.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Anusol HC Suppositories are indicated for the symptomatic relief of internal haemorrhoids and pruritus ani.


Go to top of the page
4.2 Posology and method of administration

Anal insertion.

ADULTS

Remove wrapper and insert one suppository into the anus at night, in the morning and after each evacuation.

Not to be taken orally.

ELDERLY (OVER 65 YEARS)

As for adults.

CHILDREN

Not recommended.


Go to top of the page
4.3 Contraindications

Tubercular, fungal and most viral lesions including herpes simplex, vaccinia and varicella. History of sensitivity to any of the constituents.


Go to top of the page
4.4 Special warnings and precautions for use

Following symptomatic relief, definitive diagnosis should be established.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

There is inadequate evidence of safety in human pregnancy and there may be a very small risk of cleft palate and intrauterine growth retardation as well as suppression of the neonatal HPA axis. There is evidence of harmful effects in animals. Use in pregnancy only when there is no safer alternative and when the disease itself carries risks for the mother or child.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

As with all products containing topical steroids the possibility of systemic absorption should be borne in mind.

Prolonged or excessive use may produce systemic corticosteroid effects, and use for periods longer than seven days is not recommended.

Rarely, there are sensitivity reactions. Patients may occasionally experience transient burning on application, especially if the anoderm is not intact.


Go to top of the page
4.9 Overdose

If swallowed, fever, nausea, vomiting, stomach cramps and diarrhoea may develop 3-12 hours after ingestion.

Hydrocortisone normally does not produce toxic effects in an acute single overdose. Treatment of a large acute overdose should include gastric lavage, purgation with magnesium sulphate and complete bed rest. If necessary, give oxygen and general supportive measures. Methaemoglobinaemia should be treated by intravenous methylthioninium chloride.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

This product provides antiseptic, astringent, emollient and anti-inflammatory actions.

Bismuth oxide, zinc oxide, and bismuth subgallate exert a protective action on mucous membranes and raw surfaces. They are mildly astringent and are reported to have antiseptic properties.

Balsam Peru has protective properties and a very mild antiseptic action by virtue of its content of cinnamic and benzoic acids. It is believed to promote the growth of epithelial cells.

Benzyl benzoate is used as a solubilizing agent and has mild antiseptic and preservative properties.

Hydrocortisone acetate has the general properties of hydrocortisone and the anti-inflammatory action is of primary interest in this product.


Go to top of the page
5.2 Pharmacokinetic properties

It is well known that topically applied corticosteroids can be absorbed percutaneously. This appears to be more likely upon repeated or prolonged use.

The other active ingredients in Anusol HC Suppositories exert their therapeutic effect without being absorbed into the systemic circulation. These observations are supported by evidence from various studies and reviews.


Go to top of the page
5.3 Preclinical safety data

Pre-clinical safety data do not add anything of further significance to the prescriber.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Each suppository contains:

Kaolin light

Suppocire BS2 pastilles (Hard fat)


Go to top of the page
6.2 Incompatibilities

None applicable.


Go to top of the page
6.3 Shelf life

36 months.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

Printed strip pack consisting of white opaque PVC/polyethylene laminated film. Boxes of 12 and 24 suppositories.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

McNeil Products Limited

Foundation Park

Roxborough Way

Maidenhead

Berkshire

S6 3UG

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 15513/0073


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

14th August 1998 / 14th January 2002

1st June 2002 (Transfer of Ownership)


Go to top of the page
10. DATE OF REVISION OF THE TEXT

25 February 2008



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/10495/SPC/